Biopharma
Caris Life Sciences® is at the intersection of science, medicine and information – delivering invaluable solutions to biopharma companies and researchers developing the next generation of oncology precision medicines.
Clinical Trial Services
Designed to maximize the chances of success for clinical trials and address many patient accrual challenges facing biopharma partners in the world of precision medicine.
MI Insights
Molecular Testing Capabilities
Our data-driven, molecular insights are changing the landscape of precision medicine with actionable insights from retrospective, epidemiologic, and real-time molecular data to enhance research and commercial activities.
At our 66,000 square foot, state-of-the-art laboratory located in Phoenix, Arizona, we provide high quality, reliable molecular testing services for all stages of the drug development cycle and routine clinical use.
50+
Biopharma partnerships
Just-in-Time Research
J-I-T research is a rapid start-up/enrollment process where research sites screen for patients prior to activation. Using the J-I-T approach, Pharmatech can activate research sites on clinical trials within 10-14 days. The purpose of the program is to reduce the burden on research facilities, which allows them access to a larger number of potential trials when they have an eligible patient. This allows physicians at Pharmatech J-I-T sites to include clinical trials, not yet opened, in their treatment options for current and future patients.
Molecular Testing Capabilities
- Next-Generation Sequencing (NGS): Caris has one of the most advanced sequencing laboratories in the world, which allows us to perform whole-exome DNA sequencing and whole transcriptome RNA sequencing on every patient.
-
- DNA Sequencing: Caris Molecular Intelligence® DNA sequence analysis reliably detects DNA mutations, copy number variations, and gene fusions across the entire exome. Whole-exome DNA sequencing is performed on all tumor types and for every patient. As a consequence we are able to detect mutations, copy number variations, deletions in a large number of cancer-relevant genes and are able to determine presence of genome-wide loss of heterogeneity (LOH), microsatellite-instability (MSI), as well as tumor mutational burden (TMB) with exceptional precision.
- RNA Sequencing: Whole transcriptome sequencing analysis is performed on every case and is the gold-standard method to detect clinically relevant aberrations, in particular gene-fusion events and splice variants. This is a result of the fact that RNA provides sequence information after gene splicing has happened thus avoiding the complexities of genomic features such as large intronic regions. Therefore, Caris Molecular Intelligence® has the ability to detect rare fusion events far better than DNA-based short-read methods, and provides broad coverage of all exons, capturing all possible fusion partners
- Immunohistochemistry (IHC): We evaluate protein biomarkers through an extensive immunohistochemical panel, which are applied in a tumor-type specific manner to conserve tissue and avoid unnecessary testing. Our large team of board-certified expert pathologists utilizes digital pathology and oversees application and interpretation of this technology.
- In-situ Hybridization: For select genes, we offer ISH to provide higher level of resolution to our IHC results to detect amplification and fusion events.
- Microdissection: Our Pathology team reviews every sample that is prepared for DNA and RNA sequence analysis and performs micro-dissection on every specimen, which results in a significant enrichment of the sample for DNA and RNA derived from the tumor. Because of this process, we are able to provide results in more than 95% of the cases and are able to detect molecular sub-clones present in the tumor.
Clinical Trials
Connecting patients with the most up-to-date and relevant clinical trials